Evidence map›Paper›PMID 36309752›Full record

ArticleAnnals of general psychiatry2022

A study on prescriptions contributing to the risk of high anticholinergic burden in adults with intellectual disabilities: retrospective record linkage study.

McKernan Laura Ward, Sally-Ann Cooper, Angela Henderson, Bethany Stanley, Nicola Greenlaw, Christine Pacitti, Deborah Cairns

Open access · goldAbstract read
In one paragraph

Article in Annals of general psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

McKernan Laura WardInstitute of Health and Wellbeing, University of Glasgow, Glasgow, G12 0XH, Scotland.
Sally-Ann CooperInstitute of Health and Wellbeing, University of Glasgow, Glasgow, G12 0XH, Scotland.
Angela HendersonInstitute of Health and Wellbeing, University of Glasgow, Glasgow, G12 0XH, Scotland.
Bethany StanleyRobertson Centre for Biostatistics, University of Glasgow, Glasgow, G12 8QW, Scotland.
Nicola GreenlawRobertson Centre for Biostatistics, University of Glasgow, Glasgow, G12 8QW, Scotland.
Christine PacittiGreater Glasgow & Clyde NHS, Leverndale Hospital, Glasgow, G53 7TU, Scotland.
Deborah CairnsInstitute of Health and Wellbeing, University of Glasgow, Glasgow, G12 0XH, Scotland. Deborah.Cairns@glasgow.ac.uk.
University of Glasgow · GBNHS Greater Glasgow and Clyde · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople with intellectual disabilities may face a disproportionate risk of experiencing high anticholinergic burden, and its negative sequalae, from a range of medications, and at younger ages than the general population, but there has been little previous study. Our aim was to determine the source of anticholinergic burden from prescribed medication.

methodsRetrospective matched observational study using record linkage. Adults with (n = 4,305), and without (n = 12,915), intellectual disabilities matched by age-, sex- and neighbourhood deprivation. The main outcome measure was the prescription of long-term (approximately 12 months use) anticholinergic medications overall (classified according to the Anticholinergic Risk Scale [ARS]), by drug class, individual drugs, and polypharmacy.

resultsAdults with n = 1,654 (38.4%), and without n = 3,047 (23.6%), intellectual disabilities were prescribed medications long-term with anticholinergic effects. Of those on such drugs, adults with intellectual disabilities were most likely to be on central nervous system (62.6%), gastrointestinal (46.7%), and cardiovascular (28.4%) medications. They were prescribed more central nervous system, gynaecological/urinary tract, musculoskeletal, and respiratory medications, and less cardiovascular, infection, and endocrine medications than their matched comparators. Regardless of age, sex, or neighbourhood deprivation, adults with intellectual disabilities had greater odds of being prescribed antipsychotics (OR = 5.37 [4.40-6.57], p < 0.001), antiepileptics (OR = 2.57 [2.22-2.99], p < 0.001), and anxiolytics/hypnotics (OR = 1.28 [1.06-1.56], p = 0.012). Compared to the general population, adults with intellectual disabilities were more likely to be exposed to overall anticholinergic polypharmacy (OR = 1.48 [1.33-1.66], p < 0.001), and to psychotropic polypharmacy (OR = 2.79 [2.41-3.23], p < 0.001).

conclusionsAdults with intellectual disabilities are exposed to a greater risk of having very high anticholinergic burden through polypharmacy from several classes of medications, which may be prescribed by several different prescribers. There is a need for evidence-based recommendations specifically about people with intellectual disabilities with multiple physical and mental ill-health conditions to optimise medication use, reduce inappropriate prescribing and adverse anticholinergic effects.

Indexed as

Anticholinergic burdenIntellectual disabilitiesPolypharmacyPsychotropics

Identifiers

PMID36309752
PMCPMC9617313
OpenAlexW4307810597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.